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Background: WHO guidelines recommend the lateral flow urine lipoarabinomannan assay (LF-LAM) for TB
diagnosis in hospitalised HIV-positive individuals. The role of LF-LAM among ambulant patients remains less
well defined. We investigated the sensitivity of LF-LAM among ambulant HIV-positive adults in primary health
clinics in South Africa.
Methods: We enrolled adults (aged ≥18 y) with CD4 counts of ≤150 cells/mm3 who had not received TB
treatment or antiretroviral therapy in the preceding 3 or 6 mo, respectively. Research nurses performed the
LF-LAM test on freshly voided urine. Results were compared with a reference standard of positive mycobacterial
culture (sputum or urine).
Results: Of 1505 (54.5% female; median age 37 y; median CD4 count 73 cells/mm3) participants, 973 (64.7%)
had a mycobacterial culture result; 105/973 (10.8%) were positive for Mycobacterium tuberculosis. LF-LAM
sensitivity was 41.9% (95% CI 32.3 to 51.9%) and 19.0% (95% CI 12.0 to 27.9%) using grade 1+ and grade
2+ cut-off points, respectively. Sensitivity increased with severe immunosuppression and in the presence of
poor prognostic indicators (low haemoglobin, body mass index).
Conclusions:When used as the only TB diagnostic test, LF-LAM sensitivity is suboptimal, particularly using the
grade 2+ cut-off. More sensitive tests for TB are needed that can be used in primary care settings.
Keywords: algorithms, lipoarabinomannan, South Africa, TB, TB diagnostic tests, HIV
Introduction
TB remains the leading cause of death among HIV-positive
people in low- and middle-income counties (LMIC).1 TB is often
missed and untreated in people with advanced HIV disease.2,3
The challenge of diagnosing TB in people with advanced HIV is
multifactorial, including inherent delays of mycobacterial culture
(the gold standard diagnostic test), reliance on suboptimal
sputum-based testing, high risk of extrapulmonary TB and
sputum scarcity. The development of the lateral flow urine
lipoarabinomannan assay (LF-LAM) represented an opportunity
to address some of these challenges: it is a point-of-care test
that detects lipoarabinomannan (LAM), a lipopolysaccharide
excreted in urine from an active or degenerating mycobacterial
cell wall that is released in people with active TB disease. The
assay is appropriate for use in LMIC because urine is an easy and
accessible specimen to collect, with a lower infection risk than
sputum. The results of the assay are rapid, read after 25 min by
comparing the test strip with amanufacturer-provided reference
card. Importantly, in January 2014, the manufacturer changed
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the reference card supplied with the assay from the original five
intensity bands to four intensity bands, thereby dropping the
grade 1+ cut-off point on the original reference card so that a
positive result is now represented by the old grade 2+ cut-off
only. The effect of this meant that a very low concentration of
LAM on the test strip would be interpreted as a negative test
result rather than a positive result. This change resulted in an
increase in specificity at the cost of loss of sensitivity.
In 2015, the WHO released guidelines4 for using the LF-LAM
assay (informed in part by preliminary results from our study5),
which recommended use of the assay only in HIV-positive adults,
specifically among those who are hospitalized with TB symptoms
and CD4 counts of <100 cells/mm3, or those who are ‘severely
ill’. Evidence for the guidelines was derived from several stud-
ies that evaluated LF-LAM in hospitalized HIV-positive patients.
Fewer studies evaluating the performance of LF-LAM have been
conducted in ambulant patients, therefore the utility of the test
in outpatient populations remains uncertain.
We report on a subanalysis of the TB Fast Track trial6 assessing
the sensitivity of LF-LAM among ambulant, HIV-positive adults
recruited to the intervention arm of the study.
Methods
The TB Fast Track trial was a pragmatic, open, cluster-randomised
trial conducted in 24 peri-urban and rural primary healthcare
clinics in the Gauteng, North West and Limpopo provinces,
South Africa, where HIV services were predominately nurse-
led. Recruitment to the study took place between 19 December
2012 and 18 December 2014. The study design has previously
been described.7 The intervention was nurse-initiated empirical
TB treatment, guided by a point-of-care, technology-based
algorithm, which included body mass index (BMI), haemoglobin
and LF-LAM.
HIV-positive adults (aged ≥18 y) with a CD4 count of ≤150
cells/mm3 were included. The main exclusion criteria were: any
TB treatment in the preceding 3mo; antiretroviral therapy (ART) in
the preceding 6 mo; or too sick to be managed in ambulant care.
Too sick was defined as any of: temperature >39◦C; respiratory
rate >30 breaths/min; heart rate >120 beats/min; systolic blood
pressure >180 or <90 mmHg; or any other medical condition
necessitating immediate hospital referral.
At enrolment, research nurses collected data on demograph-
ics and medical history, including using the WHO TB screening
tool to assess symptoms suggesting TB (cough, weight loss, night
sweats or fever of any duration)8; measured height and weight;
took a finger-prick blood sample for haemoglobin (Hemocue
201+, Hemocue, Angelholm, Sweden); and tested a freshly
voided urine sample with LF-LAM, as per the manufacturer’s
instructions. After 25 min, the LF-LAM result was read by com-
paring the test strip with the manufacturer’s pre-January 2014
reference card, with five intensity-level bands. In this analysis, we
show results both for grade 1+ cut-off, as recommended as of
pre-January 2014, and for grade 2+ cut-off, which corresponds
to the current recommended cut-off on the new reference cards.
A single, spontaneous, spot sputumwas collected frompartic-
ipants who were able to provide a sputum sample and this was
cultured for mycobacteria using the BACTEC MGIT 960 system
(Becton Dickinson Microbiology Systems, Cockeysville, MD, USA).
Positive cultures were assessed for species identification and
drug susceptibility using the GenoType Hain MTBDRplus assay
(Hain Lifescience GmbH, Germany). Urine samples collected at
enrolment and frozen at −80◦C were tested for mycobacterial
culture at the end of the study to strengthen the gold standard,
particularly for participants unable to produce sputum or with
extrapulmonary disease.
The inclusion criteria for this analysis were all the intervention
arm trial participants with valid LF-LAM (a visible band in the
control window of the test strip) and sputum or urine culture
results. Participants whowere sputumor urine culture positive for
non-tuberculous mycobacteria were considered negative in this
analysis.
We estimated the sensitivity of LF-LAM against a reference
standard of a positive culture for Mycobacterium tuberculosis
(MTB) from either a single sputum or urine specimen. Data were
summarised using frequencies for categorical data and medi-
ans and interquartile ranges (IQRs) for continuous data. The
sensitivity of LF-LAM was summarised with exact binomial 95%
confidence intervals (CIs). CI estimation using robust standard
errors was also conducted, adjusting for clustering at the clinic
level. LF-LAM sensitivity was summarised overall and stratified by
haemoglobin, BMI and CD4 count. Sensitivities were compared
across these strata using Fisher’s exact test. Statistical analysis
was conducted using Stata 13 (StataCorp LP, College Station, TX,
USA).
Results
Among 1507 intervention arm participants, 1505 (99.9%) had a
valid LF-LAM result. The 1505 participants were predominantly
female (820/1505 [54.5%]) and themedian age was 37 (IQR 32–
44) y. At least oneWHO TB symptomwas reported for 1095/1505
(72.8%); two or more symptoms were reported for 662/1505
(44.0%). The median CD4 count was 73 (IQR 35–111) cells/mm3;
508/1505 (33.8%) had a CD4 of ≤50 cells/mm3; 320/1505
(21.3%) had a BMI <18.5 kg/m2; and 428/1505 (28.4%) had
a haemoglobin concentration of <10 g/dL.
Of the 1505 valid LF-LAM results, 1324 (88.0%) were negative
(grade 0), 124 (8.2%) were grade 1, 20 (1.3%) were grade 2, 14
(0.9%) were grade 3, nine (0.6%) were grade 4 and 14 (0.9%)
were grade 5. The numbers of participants with positive LF-LAM
were 181/1505 (12.0%) and 57/1505 (3.8%) for grade 1+ and
grade 2+ cut-off points, respectively.
Sputum and urine culture results
A spot sputum specimen was collected in 969/1505 (64.4%)
participants (Figure 1). Of these, 102 (10.5%) were culture pos-
itive for M. tuberculosis, 853 (88.0%) were culture negative for M.
tuberculosis and 14 (1.4%) samples were contaminated. Seven
intervention arm participants had a urine sample that was M.
tuberculosis culture positive. Four had a bacteriologically positive
sputum result at enrolment (three culture positive, one smear
positive but culture negative); the remaining threewere unable to
provide sputum. The final yield of culture-positive M. tuberculosis
from either sputum or urine or both was 105/973 (10.8%).
2
D
ow
nloaded from
 https://academ
ic.oup.com
/trstm
h/advance-article-abstract/doi/10.1093/trstm
h/traa018/5822891 by guest on 26 M
ay 2020
Transactions of the Royal Society of Tropical Medicine and Hygiene
Figure 1. TB Fast Track intervention arm study participant profile. MTB, Mycobacterium tuberculosis. ∗1507 is the denominator for all percentages
displayed. †One participant with positive urine culture and negative sputum culture was sputum smear-positive.
Among the 105 participantswhowere sputum culture positive
for M. tuberculosis, LF-LAM was positive, using a grade 1+ cut-
off, in 44/105 (sensitivity 41.9% [95% CI 32.3 to 51.9%]). Using
a minimum grade 2+ cut-off, LF-LAM was positive in 20/105
(sensitivity 19.0% [95% CI 12 to 27.9%]; Table 1). Among 1389
participants who were culture negative or unable to produce
sputum, 37 had a positive LF-LAM test. Results were similar when
using robust standard errors to adjust for clustering at the clinic
level.
We further stratified LF-LAM sensitivity by subgroups at high-
est risk for mortality, those with BMI <18.5 kg/m2, haemoglobin
<10 g/dL or CD4<50 cells/mm3 (Table 1). Using a positive LF-LAM
defined by the grade 1+ cut-off, the highest sensitivity was found
in those with haemoglobin <10 vs ≥10 g/dL (53.2 vs 32.8%;
p=0.05), BMI <18.5 vs ≥18.5 kg/m2 (52.6 vs 35.8%; p=0.10) and
CD4≤50 vs 51–100 vs 101–150 cells/mm3 (48.6 vs 48.6 vs 25.8%;
p=0.10).
Discussion
The sensitivity of LF-LAM was poor in our study population of
ambulant adults with advanced HIV disease who were not yet
initiated on ART. Even after restricting the analysis to participants
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Table 1. Determine TB LAM sensitivity among sputum and urine culture positive patients for Mycobacterium tuberculosis (MTB) (n=105) overall
and stratified by body mass index (BMI), haemoglobin (Hb) and CD4 count
LF-LAM positive (≥2+) LF-LAM positive (≥1+)
n/N % (95% CI) p-value∗ n/N % (95% CI) p-value∗
Overall 20/105 19.0 (12.0 to 27.9) 44/105 41.9 (32.3 to 51.9)
Hb ≤10 g/dL 14/47 29.8 (17.3 to 44.9) 0.01 25/47 53.2 (38.0 to 67.9) 0.05
Hb >10 g/dL 6/58 10.3 (3.9 to 21.1) 19/58 32.8 (21.0 to 46.3)
BMI <18.5 kg/m2 9/38 23.7 (11.4 to 40.2) 0.44 20/38 52.6 (35.8 to 69.0) 0.10
BMI ≥18.5 kg/m2 11/67 16.4 (8.5 to 27.5) 24/67 35.8 (24.5 to 48.5)
CD4 ≤50 cells/mm3 10/37 27.0 (13.8 to 44.1) 0.19 18/37 48.6 (31.9 to 65.6) 0.10
CD4 51–100 cells/mm3 7/37 18.9 (8.0 to 35.2) 18/37 48.6 (31.9 to 65.6)
CD4 101–150 cells/mm3 3/31 9.7 (2.0 to 25.8) 8/31 25.8 (11.9 to 44.6)
LF-LAM, lateral flow urine lipoarabinomannan.
∗Fisher’s exact test, comparing sensitivities by Hb, BMI and CD4 strata.
who were severely immunocompromised (CD4 <50 cells/mm3),
LF-LAM sensitivity remained low. Overall sensitivity was reduced
by almost half when the cut-off point was changed from grade
1+ to grade 2+. This is a substantial reduction for an already
suboptimal result.
The role of the LF-LAM test among hospitalised HIV-positive
patients has been well established but the role of the test among
ambulant patients remains less well defined. Our results are
among few studies reporting the performance of LF-LAM in
ambulant HIV-positive patients. Other outpatient evaluations of
the LF-LAM test report a wide range in sensitivities between 12.5
to 41% (grade 1+)9,10 and 5.4 to 58% (grade 2+).9,11–13 This
difference reflects the differences in the participant selection,
the reference standards used and whether testing was done to
screen for or diagnose TB.
In the recent meta-analysis by Bjerrum et al., pooled sensitiv-
ity estimates for the LF-LAM test among outpatients ranged from
17.0 to 47.0% at grade 2+ cut-off.13 The four outpatient studies
included in this estimate used culture-positive M. tuberculosis
(MTB) or Xpert MTB/RIF as the reference standard for diagnosis
of TB. Our grade 2+ cut-off sensitivity of 19.6% falls at the lower
end of this range; however, two studies in the meta-analysis
excluded participants without signs or symptoms of TB and one
study included severely ill patients.
Among our study participants, 73.0% reported >1 TB symp-
tom and 44.0% ≥2 TB symptoms. A much higher sensitivity of
58.0% at the grade 2+ cut-off was reported by Huerge et al.14
using a positive Xpert MTB/RIF and MTB culture for the refer-
ence standard. Only participants reporting ≥2 wk of TB symp-
toms were included in the study. The median CD4 count was
88 cells/mm3 and almost 60% of participants met the study
criteria for ‘severely ill’ (criteria similar to those used in our study
to exclude participants). The lowest sensitivities are reported by
Hanifa et al.,9 5.4% at grade 2+ cut-off among participants with
confirmed TB (sputum culture or Xpert MTB/RIF positive). This is
despite a study population with a low median CD4 count (111
cells/mm3) and frequently reported TB symptoms (53%). The
important difference in this study is that the test was used as
a screening tool for participants already established in care, with
more than half (53%) taking ART.
Our study contributes valuable data from a large, well char-
acterised cohort of ambulant adults with advanced HIV disease
and poor prognostic indicators who would be an ideal population
for a highly sensitive non-sputum-based TB point-of care test.
Additionally, in our study, LF-LAM was performed by trained
research nurses, working under normal clinic conditions that
closely approximated the real-life setting in which the test would
be used.
Our analysis was limited because of the suboptimal reference
standard used. Only a single spot sputum and urine culture
specimen were collected to facilitate the pragmatic design of
the parent study. As a result, we may have overestimated the
sensitivity of the LF-LAM test. We do not report on the specificity
of the test, as the pragmatic study design involved minimal
TB diagnostic testing and did not allow us to determine with
certainty which participants did not have active TB at enrolment.
Conclusion
Based on findings from this study, LF-LAM is not sensitive enough
to be used as the only test for TB diagnosis in an outpatient
population, even among a very sick ambulant population.
The current recommended 2+ cut-off reduced the sensitivity
of LF-LAM substantially. Newer formulations of the LF-LAM test
that incorporate an additional concentration step to increase
sensitivity may have better potential, particularly for people
unable to produce sputum.
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